Pro Medicus (ASX:PME) Strengthens U.S. Expansion with New Cloud Deal

Aditi Sarkar

18 May 2026 04:43 PM AEST

Pro Medicus (ASX:PME) Strengthens U.S. Expansion with New Cloud Deal

Image Source: shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PME has signed a 7-year, A$90 million contract with Beth Israel Lahey Health for the full Visage 7 stack.
The platform will be implemented in the cloud under a transaction-based licensing model with potential upside.
Go-live is targeted for Q1 of the 2027 calendar year, with planning starting immediately.
CEO Dr Sam Hupert says the pipeline remains strong across all segments and full-stack deals are a continuing trend.
Investors may watch for further U.S. wins and rollout progress against the Q1 2027 milestone.

Pro Medicus Limited (ASX:PME), a leading Australian-listed healthcare imaging company, has announced that its wholly-owned U.S. Subsidiary, Visage Imaging, Inc., has signed a 7-year, A$90 million contract with Boston-based Beth Israel Lahey Health. The contract, announced to the Australian Securities Exchange on 18 May 2026, covers the full Visage 7 stack — viewer, workflow and archive — and will be implemented in the cloud under a transaction-based licensing model with potential upside. The announcement has drawn attention from Market Participants tracking PME’s ongoing momentum in the North American healthcare IT market. Following the release of the latest update, PME shares were up 2.57% to AUD 125.25 during the afternoon session on 18 May 2026, although remains down by 54.99% over the past year.

For investors monitoring the latest PME ASX announcement, the deal continues a pattern of high-value, multi-year contract wins with major U.S. health systems and provides further validation for Pro Medicus’ CloudPACS strategy. While past contracts do not guarantee future results, the update highlights the scale and structure of new agreements being signed by the company.

Latest PME ASX Announcement

The 18 May 2026 announcement, authorised by the Board of Pro Medicus Limited, sets out the headline Economics and structure of the Beth Israel Lahey Health deal. The contract has a 7-year term and is valued at A$90 million, with the company describing the arrangement as based on a transactional licensing model that provides potential upside as imaging volumes grow.

Under the agreement, Visage 7 will be implemented throughout Beth Israel Lahey Health, providing a unified diagnostic imaging platform. Visage will complete the migration from Beth Israel Lahey Health’s legacy PACS archives to Visage 7 Open Archive, and Visage 7 will deliver enterprise distribution of images integrated with the customer’s electronic health record (EHR). Planning for the rollout is to commence immediately, with go-live targeted for Q1 of calendar year 2027.

Company Background

Pro Medicus Limited (ASX:PME) is a leading healthcare informatics company founded in 1983 that provides a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide. In January 2009 the company acquired Visage Imaging, transforming the group into a global provider of leading-edge medical imaging solutions. Pro Medicus has offices in Melbourne, Berlin and San Diego.

The Visage 7 suite is the foundation of an ultra-fast, clinically rich and highly scalable platform that is deployable in both public and private cloud environments. Pro Medicus offers a leading suite of RIS, PACS, artificial intelligence and e-health solutions that the company describes as one of the most comprehensive end-to-end offerings in healthcare imaging.

Key Numbers and Financial Details

The headline financial detail in this PME ASX announcement is the A$90 million contract value over 7 years. The transaction-based licensing model means that actual Revenue contribution can vary with usage and potentially scale higher than the headline figure over the life of the contract. Pro Medicus has not disclosed in this release any new aggregate revenue guidance, cash position update or other financial metrics; those should be sourced from PME’s most recent half-year and full-year financial results and quarterly disclosures on the ASX Market Announcements Platform.

Why Investors Are Watching PME

PME is widely followed on the ASX as a benchmark for Australian-listed healthcare technology success in the North American market. CEO Dr Sam Hupert described Beth Israel Lahey Health as joining “an ever-growing list of Visage 7 clients to opt for our fully cloud-based platform,” which, “as a result of our CloudPACS strategy, is becoming the standard in the North American healthcare IT market.” Dr Hupert added that the company’s pipeline “remains strong and spans all market segments,” and that the deal is for the “‘full stack’ comprising all three core Visage products — viewer, workflow and archive — a trend we see continuing.”

Investors may watch how the Beth Israel Lahey Health rollout progresses ahead of the Q1 2027 calendar year go-live target, as well as any further full-stack cloud deals announced over coming quarters.

Share Price and Market Context

PME’s share price is set by ASX trading activity and can react to material news such as new contract announcements, broader healthcare sector sentiment, and Macroeconomic Factors. Investors interested in recent share price activity should review the ASX market data page for the PME ticker or a regulated market data provider. The 18 May 2026 contract announcement adds to the broader narrative around Pro Medicus’ U.S. growth profile.

Sector Outlook

Healthcare IT and cloud-based imaging continue to attract investor attention as health systems modernise legacy infrastructure and seek scalable platforms that integrate with electronic health records. Cloud delivery, AI-enabled imaging tools and enterprise-wide platforms are recurring themes across the sector. Pro Medicus’ Visage 7 platform sits squarely within these themes and the latest Beth Israel Lahey Health win reinforces the company’s positioning in the U.S. enterprise imaging segment.

Opportunities and Growth Drivers

Potential growth drivers for PME include continued full-stack adoption of Visage 7 by major U.S. health systems, expanding cloud-based deployments, longer contract terms, transaction-based pricing that may scale with usage, and ongoing Investment in AI-enabled imaging capabilities. Successful go-live and customer satisfaction at large systems such as Beth Israel Lahey Health may help support further pipeline conversions.

Risks and Uncertainties

Risks include implementation and integration risk during the rollout, customer concentration in large multi-year deals, foreign exchange exposure given U.S.-denominated revenue, competitive pressure from other enterprise imaging providers, and broader healthcare IT spending cycles. Forward-looking statements made by the company are inherently subject to assumptions and uncertainties, and investors should refer to PME’s formal disclosures for full risk discussion.

What Could Happen Next

Investors may watch for further updates on the Beth Israel Lahey Health rollout, additional U.S. customer wins, and any quarterly or half-year financial commentary from Pro Medicus that may discuss pipeline conversion, transaction volumes and Margin trends. The Q1 2027 calendar go-live milestone is a clear forward checkpoint.

Conclusion

PME’s 18 May 2026 ASX announcement of a 7-year, A$90 million Visage 7 cloud contract with Beth Israel Lahey Health is a notable addition to its U.S. pipeline. Investors are encouraged to read the full ASX release and monitor rollout progress as the company moves toward the Q1 2027 calendar year go-live target.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.